Elucidating the role oftransferosomes for the management of gout: A comprehensive review

Millions of people throughout the world suffer from gout, a chronic inflammatory disease. It is predominantly brought on by uric acid crystals building up in the joints, which causes excruciating pain and swelling. Conventional therapies are accessible, but their efficacy and safety are frequently limited, highlighting the need for more sophisticated and dependable therapy alternatives. Nanotechnology has become a viable option for improving drugs delivery method in recent years. Strategies utilizing liposomes, polymeric nanoparticles, metal and non-metal oxide nanoparticles, and liquid crystalline nanoparticles have demonstrated promise in enhancing bioavailability and more precisely addressing inflammatory regions. Transferosomes, a unique class of ultra-deformable, lipid-based vesicles, have drawn a lot of interest as an innovative drug delivery system for the treatment of gout. A growing amount of data from preclinical and clinical research demonstrates that transferosome-based formulations are safe and effective, and they can address many of the drawbacks of conventional gout treatments.